Radiotherapy in early stage Hodgkin's lymphoma: The importance of volume and treatment position

Radiotherapy and Oncology

Volumn 95, Issue 2, 2010, Pages 225-228

  Reymen, Bart ^a   Spiessens, Sylvie ^a   Lievens, Yolande ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Hodgkin's disease; Radiotherapy Involved node; Treatment position

Indexed keywords

ARM MOVEMENT; ARTICLE; BODY POSITION; BREAST; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HEAD; HEART VOLUME; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; INVOLVED FIELD IRRADIATION; INVOLVED NODE RADIOTHERAPY; LUNG VOLUME; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; TUMOR VOLUME; COMPARATIVE STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 77956633900     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.01.008     Document Type: Article

References (21)

1. Noordijk E, Thomas J, Fermé C et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favourable and unfavourable early stage Hodgkin's lymphoma. In: 41st Annual meeting of the american society of clinical oncology. J Clin Oncol 2005;23: 651S [abstract 6505].
2. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomised comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22: 15-8.
3. Loeffler M, Diehl V, Pfreundschuh M, et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate stage Hodgkin's disease. J Clin Oncol 1997;15: 2275-87. (Pubitemid 27251129)
4. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357: 1916-27. (Pubitemid 350074687)
5. Noordijk EM, Carde P, Mandard AM, et al. Preliminary results of the EORTC- GPMC controlled clinical trial H7 in early stage Hodgkin's disease. Ann Oncol 1994;5: 107-12. (Pubitemid 24061330)
6. The H10 EORTC/GELA randomized Intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supradiafragmatic stage I/II Hodgkin's lymphoma. EORTC 20051, Lymphoma Group, 2005.
7. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006;79: 270-7. (Pubitemid 44109907)
8. Girinsky T, Specht L, Ghalibafian M, et al. The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 2008;88: 202-10.
9. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term causespecific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21: 3431-9. (Pubitemid 46603515)
10. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin disease treated at age 50 or younger. J Clin Oncol 2002;20: 2101-8. (Pubitemid 34408801)
11. Hancock SL, Tucker MA, Hoppe RT, et al. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270: 1949-55. (Pubitemid 23312611)
12. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95: 971-80. (Pubitemid 36896714)
13. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995;87: 1530-7.
14. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97: 1428-37. (Pubitemid 41520078)
15. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94: 182-92. (Pubitemid 34162752)
16. Boice Jr JD. Radiation and breast carcinogenesis. Med Pediatr Oncol 2001;36: 508-13. (Pubitemid 32336554)
17. Hurkmans CW, Borger JH, van Giersbergen A, et al. Implementation of a forearm support to reduce the amount of irradiated lung and heart in radiation therapy of the breast. Radiother Oncol 2001;61: 193-6. (Pubitemid 33016580)
18. Canney PA, Deehan C, Glegg M, Dickson J. Reducing cardiac dose in post-operative irradiation of breast cancer patients: the relative importance of patient positioning and CT scan planning. Br J Radiol 1999;72: 986-93. (Pubitemid 29484362)
19. Girinsky T, Pichenot C, Beaudre A, et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? IJROBP 2006;64: 218-26. (Pubitemid 41831230)
20. Goodman KA, Toner S, Hunt M, et al. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. IJROBP 2005;62: 198-206. (Pubitemid 40591943)
21. Nieder C, Schill S, Kneschaurek P, Molls M. Comparison of three different mediastinal radiotherapy techniques in female patients: impact on heart sparing and dose to the breasts. Radiother Oncol 2007;92: 301-7. (Pubitemid 46341469)